Recommend maintenance therapy with lenalidomide in multiple myeloma

被引：3
|
作者：
Manasanch, Elisabet E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77007 USA
来源：
SEMINARS IN ONCOLOGY | 2016年 / 43卷 / 06期
关键词：
Myeloma; Lenalidomide; Maintenance; Transplant; STEM-CELL TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; THALIDOMIDE; SURVIVAL;
D O I：
10.1053/j.seminoncol.2016.11.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM). This showed improved progression-free survival (PFS) and in some cases, overall survival (OS). Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after ASCT in newly diagnosed MM patients has been investigated in four phase III randomized control studies. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：712 / 713
页数：2
相关论文
共 50 条
  • [1] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
    Ricardo D. Parrondo
    Victoria Alegria
    Vivek Roy
    Taimur Sher
    Asher A. Chanan-Khan
    Sikander Ailawadhi
    [J]. Annals of Hematology, 2021, 100 : 851 - 853
  • [2] Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
    Fillitz, M.
    Seebacher, A.
    Reisner, R.
    Pittermann-Hocker, E.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S90 - S90
  • [3] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
    Parrondo, Ricardo D.
    Alegria, Victoria
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (03) : 851 - 853
  • [4] Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma
    Kim, Miriam Y.
    Sposto, Richard
    Swaika, Abhisek
    Asano, Hitomi
    Alamgir, Ahsan
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    [J]. ONCOLOGY, 2014, 87 (04) : 224 - 231
  • [5] LENALIDOMIDE AS CONSOLIDATION/MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS
    Gagliardi, A.
    Della Cioppa, P.
    Lucania, A.
    Villa, M. R.
    Esposito, M.
    Improta, S.
    Izzo, G. Nitrato
    Mastrullo, L.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 593 - 593
  • [6] Lenalidomide maintenance for multiple myeloma
    Brower, Vicki
    [J]. LANCET ONCOLOGY, 2012, 13 (06): : E238 - E238
  • [7] LENALIDOMIDE CONSOLIDATION THERAPY FOLLOWED BY LENALIDOMIDE MAINTENANCE AFTER FIRST LINE THERAPY FOR MULTIPLE MYELOMA
    Takezako, N.
    Sekiguchi, N.
    Miwa, A.
    [J]. HAEMATOLOGICA, 2013, 98 : 608 - 608
  • [8] A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022
    Gupta, Ravi Kumar
    Gupta, Ashish
    Hillengass, Jens
    Holstein, Sarah A.
    Suman, Vera J.
    Taneja, Alankrita
    McCarthy, Philip L.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 457 - 469
  • [9] Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
    Brissot, E.
    Clavert, A.
    Blin, N.
    Roland, V.
    Guillaume, T.
    Dubruille, V.
    Mahe, B.
    Gastinne, T.
    Le Gouill, S.
    Gaugler, B.
    Moreau, P.
    Mohty, M.
    [J]. LEUKEMIA, 2015, 29 (10) : 2098 - 2100
  • [10] Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
    Alonso, Rafael
    Cedena, Maria-Teresa
    Wong, Sandy
    Shah, Nina
    Rios-Tamayo, Rafael
    Moraleda, Jose M.
    Lopez-Jimenez, Javier
    Garcia, Cristina
    Bahri, Natasha
    Valeri, Antonio
    Sanchez, Ricardo
    Collado-Yurrita, Luis
    Martin, Thomas
    Wolf, Jeffrey
    Lahuerta, Juan-Jose
    Martinez-Lopez, Joaquin
    [J]. BLOOD ADVANCES, 2020, 4 (10) : 2163 - 2171
12345